Trino raises €9m in funding

Dublin-based drug development firm Trino Therapeutics has received €9m in additional funding — the second major investment in a Trinity College campus company in as many months.

The money will go towards helping Trino further develop its oral drug therapy for the treatment of mild-to-moderate ulcerative colitis; an inflammatory bowel disease which affects the large intestine.

Part of the money has already been used on pre-clinical testing on the code-named PH46A treatment, with the main €7m bulk of it set to go towards bringing the drug through the formal human testing process and to complete initial Phase II trials.